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25-hydroxyvitamin D serum levels in patients with high risk
resected melanoma treated in an adjuvant bevacizumab trial
Astrid Lipplaa1,9, Ricardo Fernandes1,10, Andrea Marshall2, Paul Lorigan3, Janet Dunn2, Kevin A. Myers1,4, Emily Barker5,
Julia Newton-Bishop6, Mark R. Middleton1,7 and Pippa G. Corrie8
BACKGROUND: Studies evaluating a relationship of vitamin D in patients with primary melanoma have consistently identiﬁed an
inverse correlation with Breslow thickness, but an inconsistent impact on survival. Vitamin D in later stages of melanoma has been
less studied.
METHODS: Vitamin D was measured in serum from 341 patients with resected stage IIB–IIIC melanoma recruited to the AVAST-M
adjuvant melanoma randomised trial, collected prior to randomisation, then at 3 and 12 months. Vitamin D levels were compared
with patient demographics, known melanoma prognostic factors, disease-free interval (DFI) and overall survival (OS).
RESULTS: A total of 73% patients had stage III melanoma, 32% were enroled (and therefore tested) >1 year after primary melanoma
diagnosis. Median pre-randomisation vitamin D level was 56.5 (range 12.6–189.0 nmol/L). Vitamin D levels did not signiﬁcantly vary
over 12 months (p= 0.24). Individual pre-randomisation vitamin D levels did not differ signiﬁcantly for Breslow thickness, tumour
ulceration, or disease stage. Neither did pre-randomisation vitamin D predict for DFI (HR= 0.98 per 10 nmol/L increase; 95%
conﬁdence interval (CI) 0.93–1.04, p= 0.59) or OS (HR= 0.96 per 10 nmol/L increase, 95% CI 0.90–1.03, p= 0.31). For stage II
patients, DFI improved with higher pre-randomisation vitamin D levels for those on bevacizumab (HR= 0.74 per 10 nmol nmol/L
increase; 95% CI 0.56–0.97), but not for the observation arm (HR= 1.07 per 10 nmol/L increase; 95% CI 0.85–1.34).
CONCLUSIONS: In this stage II/III melanoma cohort, vitamin D did not correlate with known prognostic markers, nor predict for DFI
or OS, but there was some evidence of beneﬁt for patients with stage II disease treated with bevacizumab.
British Journal of Cancer https://doi.org/10.1038/s41416-018-0179-6
INTRODUCTION
Vitamin D is a pro-hormone primarily responsible for maintaining
calcium and phosphate homoeostasis in the body.1,2 Its physiolo-
gical functions include regulation of growth and differentiation in a
wide variety of normal and malignant cells.3 The hormonally
inactive pre-vitamin D is obtained from synthesis in the skin on
exposure to sunlight and to some degree through diet and
supplements. Two hydroxylation steps in the liver and kidney
transform pre-vitamin D to the circulating form, 25-hydroxyvitamin
D (25[OH]D, or vitamin D), and ultimately the active form, 1,25-
hydroxyvitamin D (1,25[OH]D, or calcitriol).4
Large epidemiological studies have shown that serum vitamin D is
inversely related to incidence and mortality of several malignancies.5
There are reported complex effects of vitamin D signalling through
the vitamin D receptor (VDR) and indeed by non-genomic effects, as
reviewed by Deeb et al.6 There are reported effects of vitamin D on
cancer cells themselves and via effects on inﬂammation, T-cell
function7 and the vasculature.8 Speciﬁcally, in vitro and in vivo studies
have demonstrated that 1,25(OH)D exerts anti-proliferative and pro-
apoptotic effects on different cancer cell lines.9–11 In melanoma,
vitamin D has been shown to diminish cell adhesion, migration and
growth of melanoma cells in vitro, as well as induce apoptosis.
The relationship between serum vitamin D levels and both
melanoma occurrence and prognosis has been investigated in a
number of studies.12–18 A meta-analysis14 identiﬁed that vitamin D
levels at the time of diagnosis were inversely related to primary
melanoma Breslow thickness, a well-established prognostic marker.
There was no independent relationship between vitamin D and risk
of melanoma recurrence, or survival. However, the meta-analysis
predates several large-scale vitamin D prospective cohort studies
and the three largest of these performed to date involving over
1000 participants each have independently reported an association
between vitamin D and melanoma relapse and/or survival.12,15,17
Other reports have suggested a relationship between VDR gene
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polymorphisms and melanoma risk19 as well as disease-speciﬁc
survival,20,21 although these data are not conclusive.
Few therapeutic trials of vitamin D supplements have been
undertaken to date and have, so far, not shown any reduction in
melanoma recurrence or incidence. The Women’s Health Initiative
randomised controlled trial found no change in melanoma
incidence in women who had taken supplements for an average
of 7 years.22 Results are pending for the Mel-D trial investigating
adjuvant treatment with vitamin D in patients with resected stage
IIB–IIIB melanoma.23,24
Most of the data correlating vitamin D levels with melanoma
prognosis come from studies performed in patients who recently
had a primary tumour resected, most of whom had a high chance of
cure from surgery. Studies, to date, have included relatively few
patients with resected locoregional melanoma, who are at much
higher risk of relapse and death from their disease. We therefore
measured serum vitamin D in a cohort of patients from the UK
AVAST-M study, which evaluated the role of the VEGF inhibitor,
bevacizumab, as adjuvant treatment for patients with resected AJCC
stage IIB–IIIC melanoma: a population whose median 5 year overall
survival was 64%.25,26
MATERIALS AND METHODS
Study design and patients
The AVAST-M trial was an open-label, randomised controlled phase 3
trial that enroled 1343 patients between 18 July 2007 and 29 March
2012 at 48 UK centres. Eligible patients were at least 16 years
old, with histological conﬁrmation of completely resected AJCC
(7th edition) stage IIB-C and IIIA-C melanoma. Patients were
randomly assigned to treatment with bevacizumab, 7.5mg/kg every
3 weeks for 1 year, or observation. Randomisation occurred within
12 weeks of surgical resection. Outcomes included overall survival
(OS) and disease-free interval (DFI). Further details and results of the
trial are reported elsewhere.25,26 We identiﬁed patients enroled in
the AVAST-M trial with suitable serum aliquots collected after their
melanoma surgery and within 28 days of trial randomisation, then at
3 and 12 months (unless relapse occurred before 12 months) for
vitamin D testing. The trial protocol required use of concomitant
medications, including supplements and complementary therapies,
to be recorded at each clinic visit.
Vitamin D measurement
We measured serum 25(OH)D (vitamin D) using liquid chromato-
graphy and mass spectrometry on samples collected pre-
randomisation, then 3 and 12 months after randomisation.
Vitamin D results were reported in nmol/L.
Statistical analysis
A power calculation was performed which suggested that a
minimum sample size of 340 patients would be sufﬁcient to
detect a standardised difference of 0.3 in vitamin D levels
between patient characteristic groups with at least 80% power
and a 5% signiﬁcance level. It was also sufﬁcient to detect a
hazard ratio of 0.65 for OS.
Box and whisker plots were constructed displaying the median,
interquartile range and ranges for the pre-randomisation
vitamin D levels depending on the month of measurement.
A generalised linear model was used to assess if the pre-
randomisation continuous vitamin D levels differed across season,
primary melanoma Breslow thickness and presence or absence of
ulceration, disease stage at randomisation, time between diag-
nosis and randomisation, as well as trial arm, after adjustment for
pre-randomisation covariates of age, gender and body mass index
(BMI), these being factors known to affect vitamin D levels. A log
transformation was used to make the assumption of normality
more appropriate. DFI was calculated as the time from randomisa-
tion until the ﬁrst tumour recurrence or date of death due to
melanoma. OS was calculated from randomisation until the date
of death from any cause. A Cox proportional hazards model was
ﬁtted to assess the association of vitamin D on OS and DFI after
adjustment for pre-randomisation covariates and trial arm
allocation. Similar analyses were undertaken for the primary
melanoma (stage II) and locoregional disease (stage III) subgroups,
although the subgroup sizes were comparatively small: 90 stage II
and 251 stage III patients made up the total cohort studied here.
For the patients with vitamin D measured over three time-
points, individual proﬁle plots were generated to identify any
patterns in changing vitamin D levels over time. Mixed effects
models were used to assess the effects of vitamin D levels over
time, accounting for the random variability between patients and
the repeated measures. These models were also adjusted for the
pre-randomisation covariates of age, gender, BMI and the season
when the measurement was taken. Mixed effects models were also
used to assess whether vitamin D levels over time differed
according to primary melanoma Breslow thickness or ulceration at
the time of initial diagnosis or disease stage at randomisation, after
adjustment for pre-randomisation covariates and season.
Role of the funding source
The sponsor and funder of the study had no role in study design,
data collection, data analysis, data interpretation or writing of this
report.
RESULTS
Evaluation of pre-randomisation vitamin D levels
A total of 341 patients from the AVAST-M trial had pre-
randomisation serum available for vitamin D measurements.
The demographic and disease characteristics of this sub-group
were similar to those for the whole trial population (Table 1 and
Corrie et al.,25). A total of 251 (73%) patients had stage III
melanoma, 137 (40%) had an ulcerated primary tumour and
120 were staged with sentinel lymph node biopsy. Pre-
randomisation vitamin D was measured in blood collected at trial
enrolment, but the primary melanoma Breslow thickness and
presence of ulceration were determined at initial diagnosis,
which may have been several years prior to AVAST-M trial entry
and randomisation in those patients who entered the trial after
resection of stage III melanoma: median time from diagnosis
to randomisation was 0.47 years, range 0–22.6 years (Table 1).
Approximately one third (108, 32%) of patients were enroled >1
year after primary melanoma diagnosis.
The median pre-randomisation vitamin D level was 56.5 nmol/L
(interquartile range 38.5–76.5 nmol/L; range 12.6–189.0 nmol/L)
(Table 2). Pre-randomisation levels were very similar for both
resected stage II and stage III subgroups. Twenty-four patients
had vitamin D levels <25 nmol nmol/L and an additional 9 patients
had vitamin D levels <45 nmol/L during the summer months of
July–September. Pre-randomisation vitamin D levels varied
according to the month in which the sample was taken. In a
generalised linear regression model after adjustment for age,
gender and BMI, vitamin D levels varied depending on the season
(p < 0.001), with higher levels from July to September (Table 2;
Fig. 1).
Twelve patients reported taking vitamin D supplements pre-
randomisation and their median vitamin D level was 67.9 nmol/L
(range 52.2–99.5). These were not the patients with the highest
vitamin D concentrations. During the subsequent 12 month
period, a further 23 patients started taking vitamin D supplements
and their median pre-randomisation vitamin D level was
50.0 nmol/L (range 19.5–119.8); only 1 patient had a vitamin D
level <25 nmol/L. For this combined cohort of 35 patients taking
vitamin D supplements, their vitamin D levels at 12 months
(median 61.6 nmol/L (range 26.8–123.7) were not signiﬁcantly
higher than for those patients who did not (median 51.2 nmol/L
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Table 1. Patient and melanoma disease characteristics
Characteristic All AVAST-M trial
patients N (%)
Vitamin D
cohort N (%)
Bevacizumab
N (%)
Observation
N (%)
Stage II
disease N (%)
Stage III
disease N (%)
1343 341 171 170 90 251
Gender
Male 753 (56) 186 (55) 88 (51) 98 (58) 58 (64) 128 (51)
Female 590 (44) 155 (45) 83 (49) 72 (42) 32 (36) 123 (49)
Age in years, median [range] 56 (18–88) 55 (19–86) 55 (19–80) 56 (19–86) 64 (23–86) 53 (19–80)
BMI kg/m2, median [range] 27.6 [15.7–68.6] 26.8 [15.8–57.6] 27.1
[15.8–57.6]
26.5
[19.4–46.2]
28.4
[19.7–40.1]
26.4
[15.8–57.6]
Time from initial melanoma diagnosis to
randomisation in years, median [range]
0.46 [0–29.3] 0.47 [0–22.6] 0.45
[0.12–18.3]
0.48 [0–22.6] 0.32
[0.13–0.45]
0.64 [0–22.6]
<1 912 (68) 233 (68) 120 (70) 113 (67) 90 (100) 143 (57)
1–2 130 (10) 40 (12) 21 (12) 19 (11) 0 40 (16)
>2 301 (22) 68 (20) 30 (18) 38 (22) 0 68 (28)
Primary melanoma Breslow thickness at diagnosis, in mm
≤2 399 (30) 103 (30) 51 (30) 52 (31) 0 103 (30)
>2–4 405 (30) 107 (31) 54 (31) 53 (31) 24 (27) 83 (33)
>4 438 (33) 111 (33) 56 (33) 55 (32) 66 (73) 45 (18)
Unknown 101 (7) 20 (6) 10 (6) 10 (6) 0 20 (6)
Primary melanoma ulceration at diagnosis
Present 518 (39) 137 (40) 70 (41) 67 (39) 67 (74) 70 (28)
Absent 633 (47) 151 (44) 68 (40) 83 (49) 20 (22) 131 (52)
Unknown 192 (14) 53 (16) 33 (19) 20 (12) 3 (3) 50 (20)
Disease stage at trial entry
II 364 (27) 90 (27) 48 (28) 42 (24)
IIIA 195 (15) 52 (15) 27 (16) 25 (15)
IIIB 495 (37) 113 (33) 54 (32) 59 (35)
IIIC 289 (21) 86 (25) 42 (24) 44 (26)
Table 2. Pre-randomisation vitamin D levels for the season when sample was taken and association with speciﬁc melanoma disease characteristics
Pre-randomisation vitamin D levels in nmol/L
N Median [interquartile range]
All patients 341 56.5 [38.6–76.5]
Timing of sample (season)
January–March 96 47.1 [30.0–69.0]
April–June 77 54.3 [36.3–75.3]
July–September 77 73.3 [57.5–90.7]
October–December 91 52.2 [38.0–68.3]
Primary melanoma Breslow thickness at diagnosis in mm
≤2 103 54.5 [36.2–72.6]
>2-4 107 56.9 [39.1–82.3]
>4 111 56.9 [43.1–75.7]
Unknown 20 56.3 [38.9–82.4]
Primary melanoma ulceration
Present 137 54.9 [41.0–76.7]
Absent 151 60.1 [36.9–77.2]
Unknown 53 53.3 [39.1–71.2]
Disease stage at trial entry
II 90 55.6 [42.3–76.6]
III 251 56.6 [37.7–76.5]
Time from initial melanoma diagnosis to randomisation in years
<1 233 56.5 [40.0–76.6]
1–2 40 54.3 [36.3–75.9]
>2 68 57.2 [37.4–71.6]
Trial arm
Bevacizumab 171 52.6 [37.5–76.7]
Observation 170 59.8 [39.8–76.5]
25-hydroxyvitamin D serum levels in...
A Lipplaa et al.
3
(range 10.3–166.2; p= 0.10 unadjusted, p= 0.07 adjusted for age,
gender, BMI and season).
In a generalised linear regression model, pre-randomisation
vitamin D levels did not differ signiﬁcantly for primary melanoma
Breslow thickness (p= 0.72), ulceration (p= 0.33), disease stage
at trial entry (p= 0.25), time between diagnosis (p= 0.23) and
randomisation, or trial arm (p= 0.84), after adjustment for age,
gender, BMI, and season (Table 3). The ﬁndings were not
signiﬁcantly different when analysed separately by disease stage
II and III subgroups.
Of the 341 patients in this analysis, 120 (35%) have died; 109
(91%) from metastatic melanoma. The median follow-up for the
221 surviving patients was 6 years. Pre-randomisation vitamin D
level did not predict for OS (HR= 0.96 per 10 nmol/L increase
(95% conﬁdence interval (CI) 0.90–1.03); p= 0.31) after adjustment
for age, gender, BMI, season, and trial arm. A total of 169 (50%)
had relapsed either locally or distantly. Pre-randomisation vitamin
D level did not predict for DFI (HR= 0.98 per 10 nmol/L increase
(95% CI 0.93–1.04); p= 0.59) after adjustment for age, gender, BMI,
season, and trial arm. The 24 patients classiﬁed as being vitamin D
deﬁcient (<25 nmol/L27) did not have signiﬁcantly worse out-
comes in terms of OS (p= 0.42) or DFI (p= 0.78), compared with
those patients with higher vitamin D levels.
There was no signiﬁcant interaction between trial arm and
vitamin D levels for OS (p= 0.70) or DFI (p= 0.29). Similar results
within the disease stage II and III subgroups were seen, with
one exception: for the stage II subgroup, there was a signiﬁcant
interaction between vitamin D and trial arm for DFI (p= 0.03),
which was not seen for the stage III subgroup or the combined
cohort (Table 4). For stage II patients randomised to bevacizumab,
DFI improved with higher pre-randomisation vitamin D levels
(HR= 0.74 per 10 nmol/L increase; 95% CI 0.56–0.97). This was
not the case for the observation arm (HR= 1.07 per 10 nmol/L
increase; 95% CI 0.85–1.34).
Vitamin D levels over time
A total of 175 (51%) of the 341 patients had vitamin D
measurements available at all three time points: pre-randomisa-
tion, 3 and 12 months after randomisation. There was no
consistent pattern for any changes in vitamin D levels over time.
For individuals, vitamin D varied over the three time-points by a
median 20.4 nmol/L (interquartile range 11.1–32.0, range
0.4–116.3). The median vitamin D level at each time-point was
similar (Supplementary Table 1).
Pre-randomisation vitamin D levels varied according to the
season of the year, with higher levels during July–September
and similar patterns were seen in samples taken at 3 and
12 months. After adjustment for age, gender and BMI, the
seasonal variation was statistically signiﬁcant (p < 0.001), but
no variation between the three time-points was observed
(p= 0.24). There was also no association between vitamin D
levels over time and primary melanoma Breslow thickness
200
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Fig. 1 Plots of pre-randomisation vitamin D levels against the month the sample was taken. Boxes represent interquartile range of vitamin D
(nmol/L), whiskers represent range
Table 3. Associations of melanoma disease characteristics and pre-
randomisation vitamin D levels
Characteristic Total
p-value
Disease
stage II
p-value
Disease
stage III
p-value
Number of patients 341 90 251
Season <0.001 0.02 <0.001
Primary melanoma Breslow
thickness at diagnosis, in mm
0.72 0.59 0.78
Primary melanoma ulceration
at diagnosis
0.33 0.83 0.23
Time from initial melanoma
diagnosis to randomisation in
years, median [range]
0.23 a 0.30
Trial arm 0.84 0.64 0.96
P-values reported from a GLM model for pre-randomisation vitamin D
levels and after adjustment for age gender, BMI, and season. aCannot
calculate for stage II as all were within the same group
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(p= 0.30), ulceration (p= 0.41) or disease stage at trial entry
(p= 0.17, Supplementary Table 1).
DISCUSSION
We performed an exploratory study to measure vitamin D in a
cohort of melanoma patients who took part in the AVAST-M trial,
an adjuvant trial investigating the use of bevacizumab in patients
with melanoma at a high risk of recurrence. At the time of
initiating AVAST-M, angiogenesis inhibition was a relevant target
for cancer adjuvant therapy, including melanoma, based on early
signals of efﬁcacy in metastatic disease.28 Since there was no
known pharmacological interaction between bevacizumab and
vitamin D, we made use of serial blood samples collected from
patients in both the observation and treatment arms and explored
relationships of vitamin D with disease characteristics and
outcomes after surgery, including disease recurrence and survival.
In comparison with primary melanoma populations in whom
vitamin D has been studied to date, the sample size of our study
was relatively small: 341 patients had available pre-randomisation
vitamin D measurements and half of these had subsequent
measurements performed during the ﬁrst year of follow-up. Even
so, consistent with the previously reported literature,29–31 we
found strong evidence that vitamin D varied seasonally, with the
highest serum levels from July to September.
In contrast to the larger scale primary melanoma studies, which
have reported an association between vitamin D and melanoma
relapse and/or survival (Table 5), our study in patients with
predominantly later stage disease showed no evidence that
vitamin D was an independent prognostic marker after surgical
resection. Our cohort comprised 90 resected stage II and 251
resected stage III patients. Within these smaller subgroups, the
ﬁndings were no different to the whole population.
Our ﬁndings could still be consistent with an anti-cancer effect
of vitamin D in the early stages of carcinogenesis, which is lost
once the cancer progresses. The genomic effects of vitamin D are
mediated when 1,25:dihydroxyvitamin D is bound to a hetero-
dimeric receptor formed from the retinoid X receptor (RXR) and the
vitamin D receptor (VDR).32 Vitamin D is also known to have non-
genomic effects.6 The antiproliferative effects of vitamin D on
normal and cancer cells in vitro are well described10 and there is
good evidence that some of those effects at least are mediated by
the induction of E-cadherin.33 Evidence that the majority of the
antiproliferative effects are genomically mediated by VDR has been
reported after the restoration of growth inhibitory effects of
vitamin D in VDR null murine cells, engineered to stably express
VDR.34 The observation of a correlation between vitamin D levels
and the thickness of primary melanoma at diagnosis in previously
published studies (Table 5) is consistent with the hypothesis that
low vitamin D may contribute to the growth of primary melanoma.
It is known however that there is progressive loss of expression of
VDR with melanoma progression35 and it is therefore likely that
any protective effect of vitamin D on cell proliferation will be
diminished or lost in more advanced tumours.
Vitamin D is known to have complex effects on cells and of
particular concern for cancer is a wealth of literature suggesting
that vitamin D mediates an immunosuppressive effect in
humans.36,37 We have therefore expressed concern previously
that there might be a narrow therapeutic window for a putative
beneﬁcial effect of vitamin D in melanoma38 and the view
that a conservative approach to supplementation should be
adopted in order to avoid higher serum levels to avoid potential
harm.39 A transcriptomic study40 reported evidence that higher
vitamin D levels in melanoma patients were associated with less
proliferative tumour phenotypes and a greater likelihood of a
stronger immune gene signature. This is reassuring from a safety
point of view, but it remains of concern that in the presence of
loss of expression of VDR, higher vitamin D levels might be
associated with adverse outcomes for poorer prognosis mela-
noma patients rather than having a protective effect. In our study,
we saw no evidence that higher vitamin D levels were associated
with a deleterious effect on survival, although the sample size was
quite small.
There is an obvious major difference in our approach compared
with previously published series. Compared with most other
studies, which measured vitamin D after resection of primary
melanoma, in our cohort blood samples were taken predomi-
nantly from patients after resection of regional lymph nodes,
representing relapse of disease sometimes years after the initial
diagnosis and treatment of their primary melanoma. For many of
our patients there was ample time for their health behaviour to
change between their primary diagnosis and the melanoma event
that occasioned trial entry. Vitamin D levels might therefore reﬂect
overall health and modiﬁed sun exposure or dietary intake,
instead of being a causal factor in melanoma recurrence, while the
vitamin D level measured at the time of trial entry may not reﬂect
that at the time of primary melanoma diagnosis when tumour
thickness was determined.
Vitamin D levels were higher overall in our cohort compared to
the previous studies performed by Newton-Bishop et al.12 and Saiag
et al.15: only 7% of our patient cohort would have been classiﬁed
as vitamin D deﬁcient using a nationally agreed deﬁnition of
<25 nmol/L.27 Ten percent of the patients we studied were taking
vitamin D supplements. Although only 1 of these patients had
Table 4. Association of vitamin D levels with disease-free interval and overall survival
Characteristic Vitamin D cohort Stage II subgroup Stage III subgroup
Number of patients 341 90 251
Overall survival
Vitamin D HR= 0.96 (95% CI 0.90–1.03);
p= 0.31
HR= 0.89 (95% CI 0.74–1.08);
p= 0.24
HR= 0.98 (95% CI 0.91–1.06);
p= 0.61
Vitamin D and trial arm interaction P= 0.70 P= 0.58 P= 0.59
Disease-free interval
Vitamin D HR= 0.98 (95% CI 0.93–1.04);
p= 0.59
HR= 0.91 (95% CI 0.77–1.08);
p= 0.27
HR > 0.99 (95% CI 0.94–1.06);
p= 0.98
Vitamin D and trial arm interaction P= 0.29 p= 0.03 P= 0.74
Vitamin D for Bevacizumab arm only HR= 0.74 (95% CI 0.56–0.97)
Vitamin D for Observation arm only HR= 1.07 (95% CI 0.85–1.34)
aAll hazard ratios for vitamin D are for a 10 nmol/L increase in vitamin D level and obtained after adjustment for age gender, BMI, and season.
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pre-randomisation vitamin D level <25 nmol/L, taking supplements
did not ensure the highest vitamin D levels.
Of note, the only signiﬁcant correlation with outcomes we
identiﬁed was that higher pre-randomisation vitamin D levels
predicted for longer DFI in the bevacizumab-treated stage II
patients only. The relevance of this ﬁnding is not clear and given
the very small sample size, it could be a chance ﬁnding. On the
other hand, current literature suggests that vitamin D has both
anti-angiogenic and pro-angiogenic effects8 and the fact that this
outcome was identiﬁed only in the stage II subgroup may be
evidence of vitamin D exerting an inﬂuential effect in the earlier
stages of tumour invasion. In the context of metastatic colorectal
cancer, a randomised phase II trial recently reported improved
progression-free survival when patients treated with standard
bevacizumab+mFOLFOX6 systemic therapy received high versus
low vitamin D supplementation.41 A positive interaction between
vitamin D and bevacizumab with therapeutic potential cannot, at
this stage, be discounted.
In conclusion, as previously reported, we have shown seasonal
variation in vitamin D levels. In contrast to published studies
previously describing a relationship between vitamin D and
primary melanoma thickness, in this study of 341 patients with
later stage resected stage II–III melanoma recruited to the AVAST-
M trial, there was no correlation between vitamin D and primary
melanoma Breslow thickness, ulceration or disease stage. Overall,
Vitamin D levels did not predict for subsequent relapse or survival.
These ﬁndings contrast with stronger reported associations with
melanoma stage at diagnosis and may reﬂect changes in
biological effects of vitamin D at later stages of the disease. The
observation of a better DFI in bevacizumab-treated stage II
patients with higher levels of vitamin D warrants further
exploration before justifying future exploitation.
ACKNOWLEDGEMENTS
This project received additional support from the Oxford NIHR Biomedical Research
Centre and Oxford Experimental Cancer Medicine Centre. AVAST-M was an NIHR
portfolio study conceived by the NCRI Skin Cancer Clinical Studies Group. We are
grateful to all the patients, their families, investigators and their support staff who
contributed to the AVAST-M trial.
AUTHOR CONTRIBUTIONS
Conception and design: M.R.M., A.M., J.N.-B., P.G.C., and P.L. Acquisition of data: E.B., A.
M., A.L., R.F., and K.A.M. Analysis and interpretation of data: A.M., A.L., R.F., J.D., M.R.M.,
P.G.C., and P.L. Drafting of manuscript: P.G.C., M.R.M., A.M., A.L., and R.F. All authors
take responsibility for the integrity of the data and the accuracy of the data analysis.
Critical revision of the manuscript for important intellectual content and ﬁnal
approval of the manuscript: All authors.
ADDITIONAL INFORMATION
Supplementary information is available for this paper at https://doi.org/10.1038/
s41416-018-0179-6.
Ethics approval and consent to participate: Regulatory approval and ethics
approval from a multicentre ethics committee NRES Committee South Central—
Oxford C were obtained (07/Q1606/15) and all patients gave written informed
consent. The study was performed in accordance with the Declaration of Helsinki.
Funding: Cancer Research UK C7535/A6408 (AVAST-M Clinical Trial) and C2195/
A8466 (Predicting Relapse of Melanoma).
Competing interests: P.G.C. reports personal fees from Novartis, MSD, BMS and
Incyte, personal fees and grants from Celgene, outside the submitted work. M.R.M.
reports personal fees from Amgen, grants and personal fees from Roche and GSK,
grants from Astrazeneca, personal fees and other from Novartis, Rigontec and Array
Biopharma, other from Astellas (was OSI) and Millenium, non-ﬁnancial support and
other from Immunocore, personal fees and other from BMS and Eisai, personal fees,
non-ﬁnancial support and other from Merck, personal fees from Cytomx, Bioline
and Valo Therapeutics, other from Regeneron, Vertex, TCBiopharma, Pﬁzer and
Replimune, outside the submitted work. P.L. reports personal fees and other from
Agenus, Amgen, BMS, GSK, Lytix Biopharma, Merck, MSD, Nektar and Novartis,
personal fees from NeraCare, grants, personal fees and other from Roche, outside
the submitted work. The remaining authors declare no competing interests.
REFERENCES
1. Holick, M. F. Vitamin D and bone health. J. Nutr. 126, 1159S–1164SS (1996).
2. Jones, G., Strugnell, S. A. & DeLuca, H. F. Current understanding of the molecular
actions of vitamin D. Physiol. Rev. 78, 1193–1231 (1998).
3. Adams, J. S. & Hewison, M. Unexpected actions of vitamin D: new perspectives on
the regulation of innate and adaptive immunity. Nat. Clin. Pract. Endocrinol.
Metab. 4, 80–90 (2008).
4. Christakos, S., Dhawan, P., Verstuyf, A., Verlinden, L. & Carmeliet, G. Vitamin D:
metabolism, molecular mechanism of action, and pleiotropic effects. Physiol. Rev.
96, 365–408 (2016).
5. Budhathoki, S. et al. Japan Public Health Center-based Prospective Study Group.
Plasma 25-hydroxyvitamin D concentration and subsequent risk of total and site
speciﬁc cancers in Japanese population: large case-cohort study within Japan
Public Health Center-based Prospective Study cohort. Br. Med. J. 360, k671 (2018).
6. Deeb, K. K., Trump, D. L. & Johnson, C. S. Vitamin D signalling pathways in cancer:
potential for anticancer therapeutics. Nat. Rev. Cancer 7, 684–700 (2007).
7. Bickle, D. D. Clinical counterpoint: vitamin D: new actions, new analogs, new
therapeutic potential. Endo Rev. 13, 765–784 (1992).
8. Soodabeh, A., Mehrangiz, E. -M. A systemic review of vitamin D and angiogenesis.
BMJ Open 2017; https://doi.org/10.1136/bmjopen-2016-015415.7.
9. Evans, S. R. et al. Vitamin D receptor and growth inhibition by 1,25-dihydrox-
yvitamin D-3 in human malignant melanoma cell lines. J. Surg. Res. 61, 127–133
(1996).
10. Hansen, C. M., Binderup, L., Hamberg, K. J. & Carlberg, C. Vitamin D and cancer:
effects of 1,25(OH)(2)D-3 and its analogs on growth control and tumorigenesis.
Front. Biosci. 6, D820–D848 (2001).
11. Osborne, J. E. & Hutchinson, P. E. Vitamin D and systemic cancer: is this relevant
to malignant melanoma? Br. J. Dermatol. 147, 197–213 (2002).
12. Newton-Bishop, J. A. et al. Serum 25-Hydroxyvitamin D(3) levels are associated
with breslow thickness at presentation and survival from melanoma. J. Clin.
Oncol. 27, 5439–5444 (2009).
13. Gambichler, T., Bindsteiner, M., Hoxtermann, S. & Kreuter, A. Serum
25-hydroxyvitamin D serum levels in a large German cohort of patients with
melanoma. Br. J. Dermatol. 168, 625–628 (2013).
14. Caini, S. et al. Vitamin D and melanoma and non-melanoma skin cancer risk and
prognosis: a comprehensive review and meta-analysis. Eur. J. Cancer 50,
2649–2658 (2014).
15. Saiag, P. et al. Prognostic value of 25-hydroxyvitamin D3 levels at diagnosis and
during follow-up in melanoma patients. J. Natl Cancer Inst. 107, djv264 (2015).
16. Wyatt, C., Lucas, R. M., Hurst, C. & Kimlin, M. G. Vitamin D deﬁciency at melanoma
diagnosis is associated with higher Breslow thickness. PLoS ONE 10, 1–13 (2015).
17. Fang, S. et al. Association of vitamin D levels with outcome in patients with
melanoma after adjustment for C-reactive protein. J. Clin. Oncol. 34, 1741–1747
(2016).
18. Timerman, D. et al. Vitamin D deﬁciency is associated with a worse prognosis in
metastatic melanoma. Oncotarget 8, 6873–6882 (2017).
19. Randerson-Moor, J. A. et al. Vitamin D receptor gene polymorphisms, serum
25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and
a meta-analysis of published VDR data. Eur. J. Cancer 45, 3271–3281 (2009).
20. Orlow, I. et al. Vitamin D receptor polymorphisms and survival in patients
with cutaneous melanoma: a population-based study. Carcinogenesis 37, 30–38
(2016).
21. Luo, L. et al. No prognostic value added by vitamin D pathway SNPs to current
prognostic system for melanoma survival. PLoS ONE 12, e0174234 (2017).
22. Tang, J. Y. et al. Calcium plus vitamin D supplementation and the risk
of nonmelanoma and melanoma skin cancer: post hoc analyses of the
women’s health initiative randomized controlled trial. J. Clin. Oncol. 29,
3078–3084 (2011).
23. Saw, R. P. et al. Adjuvant therapy with high dose vitamin D following primary
treatment of melanoma at high risk of recurrence: a placebo controlled rando-
mised phase II trial (ANZMTG 02.09 Mel-D). BMC Cancer 14, 780 (2014).
24. Saw, R. P., et al. High dose vitamin D following primary treatment of melanoma
at high risk of recurrence: a pilot placebo controlled randomised phase II
trial assessing feasibility: safety and toxicity (ANZMTG 02.09 MEL-D trial).
Proceedings of 9th World Congress of Melanoma abstr 2017; SY20–SY26.
25. Corrie, P. G. et al. Adjuvant bevacizumab in patients with melanoma at high risk
of recurrence (AVAST-M): preplanned interim results from a multicentre, open-
label, randomised controlled phase 3 study. Lancet Oncol. 15, 620–630 (2014).
25-hydroxyvitamin D serum levels in...
A Lipplaa et al.
7
26. Corrie, P. G. et al. Adjuvant bevacizumab as treatment for melanoma patients at
high risk of recurrence: ﬁnal resulsts for the AVAST-M trial. J. Clin. Oncol. 35
(suppl), 9501 (2017).
27. Scientiﬁc Advisory Committee on Nutrition. Vitamin D and Health, 2016 https://
www.gov.uk/government/groups/scientiﬁc-advisory-committee-on-nutrition
28. Kim, K. B. et al. BEAM: a randomized phase II study evaluating the
activity of bevacizumab in combination with carboplatin plus paclitaxel in
patients with previously untreated advanced melanoma. J. Clin. Oncol. 30, 34–41
(2012).
29. McLauchlan, M. et al. Seasonal-variations in serum 25-hydroxycholecalciferol in
healthy people. Lancet 1, 536–538 (1974).
30. Stamp, T. C. B. & Round, J. M. Seasonal-changes in human plasma-levels of
25-hydroxyvitamin-D. Nature 247, 563–565 (1974).
31. Klingberg, E., Olerod, G., Konar, J., Petzold, M. & Hammarsten, O. Seasonal var-
iations in serum 25-hydroxy vitamin D levels in a Swedish cohort. Endocrine 49,
800–808 (2015).
32. Thompson, P. D. et al. Vitamin D receptor displays DNA binding and transacti-
vation as a heterodimer with the retinoid X receptor, but not with the thyroid
hormone receptor. J. Cell Biochem. 75, 462–480 (1999).
33. Pálmer, H. G. et al. Vitamin D(3) promotes the differentiation of colon carcinoma
cells by the induction of E-cadherin and the inhibition of beta-catenin signaling.
J. Cell Biol. 154, 369–387 (2001).
34. Keith, M. R., LaPorta, E. & Welsh, J. Stable expression of human VDR in murine
VDR-null cells recapitulates vitamin D mediated anti-cancer signaling. Mol. Car-
cinog. 53, 286–299 (2014).
35. Brozyna, A. A., Jozwicki, W., Janjetovic, Z. & Slominski, A. T. Expression of
vitamin D receptor decreases during progression of pigemented skin lesions.
Hum. Pathol. 42, 618–631 (2011).
36. Boonstra, A. et al. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive
CD4(+) T cells to enhance the development of Th2 cells. J. Immunol. 167,
4974–4980 (2001).
37. Grifﬁn, M. D. et al. Dendritic cell modulation by 1a,25 dihydroxyvitamin D3
and its analogs: a vitamin D receptor-dependent pathway that promotes a
persistent state of immaturity in vitro and in vivo. Proc. Natl Acad. Sci. USA 98,
6800–6805 (2001).
38. Field, S. & Newton-Bishop, J. A. Melanoma and vitamin D. Mol. Oncol. 5, 197–214
(2011).
39. O’Shea, S. J., Davies, J. R. & Newton-Bishop, J. A. Vitamin D, vitamin A, the primary
melanoma transcriptome and survival. Br. J. Dermatol. 175(Suppl 2), 30–34 (2016).
40. Nsengimana, J. et al. Independent replication of a melanoma subtype gene
signature and evaluation of its prognostic value and biological correlates in a
population cohort. Oncotarget 6, 11683–11693 (2015).
41. Ng, K. et al. SUNSHINE: randomized double-blind phase II trial of vitamin D
supplementation in patients with previously untreated metastatic colorectal
cancer. J. Clin. Oncol. 35(suppl), 3506–3506 (2017).
42. Nürnberg, B. et al. Reduced serum 25-Hydroxyvitamin D levels in stage IV
melanoma patients. Anticancer Res. 29, 3669–3674 (2009).
43. Ogbah, Z. et al. Serum 25-hydroxyvitamin D3 levels and vitamin D receptor
variants in melanoma patients from the Mediterranean area of Barcelona.
BMC Med. Genet 14, 26 (2013).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2018
25-hydroxyvitamin D serum levels in...
A Lipplaa et al.
8
